TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $2.82M |
| Net Income (Most Recent Fiscal Year) | $-127.50M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 18.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2974.08% |
| Net Margin (Trailing 12 Months) | -2974.08% |
| Return on Equity (Trailing 12 Months) | -55.76% |
| Return on Assets (Trailing 12 Months) | -36.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.55 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.15 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.13 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 56.59M |
| Free Float | 54.13M |
| Market Capitalization | $82.06M |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | 0.98 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.35% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |